Focus Partners Advisor Solutions LLC Buys 1,105 Shares of Medpace Holdings, Inc. $MEDP

Focus Partners Advisor Solutions LLC raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,592 shares of the company’s stock after acquiring an additional 1,105 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Medpace were worth $3,141,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. AQR Capital Management LLC increased its stake in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares in the last quarter. Wasatch Advisors LP increased its stake in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after buying an additional 116,354 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after buying an additional 24,625 shares in the last quarter. Invesco Ltd. increased its stake in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after buying an additional 85,517 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Medpace by 92.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after buying an additional 166,654 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Trading Up 1.9%

Medpace stock opened at $466.79 on Wednesday. The firm has a market capitalization of $13.33 billion, a P/E ratio of 29.34, a PEG ratio of 2.32 and a beta of 1.18. Medpace Holdings, Inc. has a 1 year low of $294.07 and a 1 year high of $628.92. The business has a 50-day moving average of $456.86 and a 200-day moving average of $506.57.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period in the previous year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Activity at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 20.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

MEDP has been the subject of a number of research reports. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Royal Bank Of Canada lowered their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research report on Friday, February 13th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Robert W. Baird lowered their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.